Pfizer’s Elrexfio has taken another step on its path to potential commercial momentum: The drugmaker just announced another ...

A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...

A biologics license application (BLA) for etentamig (ABBV-383) has been submitted to the FDA for the treatment of adults with ...

Pfizer (PFE) stock is in focus as the company succeeeds in a late-stage trial for multiple myeloma therapy, Elrexfio in an ...

Pfizer (PFE) said Tuesday that the phase 3 MagnetisMM-32 study of Elrexfio in adults with relapsed or refractory multiple myeloma met its primary endpoint of progression-free surv ...

Pfizer Inc. announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received ...

AbbVie (NYSE: ABBV) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for etentamig, a second-generation BCMA x CD3 bispecific ...

Nearly half of patients with multiple myeloma experience pathological fractures, according to a retrospective analysis of 692 ...

Black Americans are more likely to develop multiple myeloma and are often diagnosed at a younger age. The reasons are not fully understood but may involve biological and genetic factors. MGUS, a ...

In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...

AbbVie announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager ...